103 results about "Idiotype" patented technology

A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too.

The invention relates, among other things, a preparation comprising Alzheimer's disease antigen (A68), as well as methods of obtaining this purified antigen, and methods of using this purified antigen, for instance, for diagnosing Alzheimer's disease and for detecting human autoantibodies to the Alzheimer disease antigen. The antigen preparation according to the invention is purified in that it is substantially free of immunoglobulin G. The invention further relates to methods of making Alzheimer disease antigens that can be used instead of or along with the A68 antigen preparation (e.g., for diagnosing AD), such as recombinant human tau, tau isolated from various species including human, and phosphorylated recombinant human tau or isolated tau, as well as A68 anti-idiotypic antibodies.

The presence and quantity of an antibody of interest in a patient's bloodstream or other biological sample can serve as an important clinical or other analytical or diagnostic tool. ELISA methods, and kits for such assays, as well as anti-idiotypic antibodies and hybridomas producing them, are developed to detect levels of the antibody in biological samples, which are from, for example, animal models and human patients.

The invention relates to Ab2-type anti-idiotypic antibodies and fragments thereof which mimic HVI-1 epitopes that are otherwise cryptic to the immune system and which antibodies or fragments thereof are directed against potently neutralizing anti-HIV-1 antibodies. The invention further relates to a hybridoma cell line 3H6 expressing the anti-idiotypic antibody and to pharmaceutical compositions containing the antibody or fragment thereof. The invention also relates to HIV-1 neutralizing Ab3-type antibodies elicited upon administration of the Ab2-type anti-idiotypic antibody or fragment thereof and to pharmaceutical compositions containing them. The invention also relates to the use of the present antibodies or fragments thereof as screening tools or as diagnostic or therapeutic agents.

The present invention concerns methods for selecting and producing idiotype vaccines, and in particular methods for selecting and producing an idiotype vaccine for treatment of a B-cell derived malignancy in a subject based on the clonal profile (clonotype) of the malignancy; a method for producing an updated idiotype vaccine matched to a B-cell derived malignancy exhibiting a shifting clonal profile; and the high-fidelity idiotype vaccines produced using the methods. The invention also includes idiotype vaccines produced using the described methods and methods of treating B-cell derived malignancies using the produced vaccines.

A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too.

The present invention provides an anti-idiotypic antibody having specific reactivity with an idiotope common to more than one type of anti-HIV-1 antibody, and having no specific reactivity with non-HIV-1 antibodies. The present invention provides methods of diagnosis, monitoring and treatment of HIV-related diseases through the use of this antibody or related compounds.

The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.

A binding partner for the TSH receptor, which binding partner comprises, or is derived from, a human monoclonal or recombinant antibody, or one or more fragments thereof, reactive with the TSH receptor, uses thereof, methods of diagnosis and therapy employing the same, and anti-idiotypic antibodies thereto.

The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the domain A2 of Factor VIII, and to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as drug, and more particularly, to its use for the manufacturing of a drug to be used for the treatment of haemophilia A.

The invention discloses an envelope protein VP28 idiotype monoclonal antibody against shrimp white spot syndrome virus (WSSV) and a preparation method thereof. The antibody is secreted by a hybridoma cells with the collection number of CCTCC-CT200938, is prepared by taking anti-WSSV-VP28 monoclonal antibody (Ab1) as antigen, can bind with anti-WSSV-VP28 antibody of hare, and has the capability of competing with WSSV to bind with the anti-WSSV-VP28 antibody of the hare. The anti-WSSV-VP28 idiotype monoclonal antibody (Ab3) prepared by taking the antibody as antigen can bind with the WSSV, the binding site of the anti-WSSV-VP28 idiotype monoclonal antibody (Ab3) and the WSSV is located on an envelope, and the Ab3 can neutralize WSSV infection and has Ab1 properties. In the invention, the idiotype antibody is applied in the research of WSSV for the first time; a screening system is established, which uses an indirect enzyme-linked immunosorbent assay (ELISA) method and a competitive enzyme-linked immunosorbent assay (ELISA) method for detection; the fact that Ab3 has properties of Ab1 is proved by adopting an indirect immnnofluotesent method (IIF), a gold labeling immunoelectron microscopic method and crayfish in vivo neutralization tests, thus proving that the monoclonal antibody in the invention has the property to simulate original antigen WSSV-VP28.

The present invention provides combination immunotherapy for Non-Hodgkin's Lymphoma. In one embodiment, the combination immunotherapy first provides for the administration of a monoclonal antibody directed to a non-idotypic portion of a lymphoma cell surface immunoglobulin (e.g. a framework region of a variable region). The combination immunotherapy next provides for the administration of an immunogenic composition comprising at least a portion of the same lymphoma cell surface immunoglobulin, whether an idiotypic portion or non-idiotypic portion.

The invention discloses human-derived insecticidal protein. The coded nucleotide sequence of the human-derived insecticidal protein is as shown in SEQ ID NO.5, and the amino acid sequence of the human-derived insecticidal protein as shown in SEQ ID NO.6. Orthomutation is conducted on anti-Cry1B toxin idiotype single-chain antibody C7 to form a saturation mutagenesis library, then the saturation mutagenesis library is screened through a phage display technology, and the human-derived insecticidal protein is obtained; the affinity with insects BBMV of the human-derived insecticidal protein is remarkably higher than that of antibody C7 without mutation, the human-derived insecticidal protein can replace Cry1B toxin effectively to be used for biological control over pests, the human-derived insecticidal protein and C7 belong to a humanized antibody, and the human-derived insecticidal protein does less harm to the human body when used as biological pesticide.

The invention relates to a nucleic acid construct for delivery into living cells in vivo for inducing an immune response in a patient to an idiotypic determinant present on a malignant B cell in the patient; the construct directing the expression of a fusion protein, said fusion protein comprising the idiotypic determinant and at least one T helper cell epitope from tetanus toxin. The invention further relates to a method of making the nucleic acid construct, a method of treating a patient, and to a composition comprising the nucleic acid construct.

The present invention relates to idiotypic vaccine compositions for use in inducing immunity to p53. The invention preferably relates to a vaccine composition comprising a pharmaceutically acceptable carrier and at least one peptide, wherein the at least one peptide is selected from the group consisting of X1-LLQALKH-Y1, X2-FIRKAYGAATAYAASKKG-Y2 and X3-MQGLQTPYT-Y3 in which X1, X2, X3, Y1, Y2 and Y3 are independently either absent or an amino acid sequence of preferably less than 10 amino acids which provides a framework for the specified peptide.

Vaccines capable of eliciting an immune antitumor response for prostate tumors are disclosed. The active ingredient in such vaccines is selected from the group consisting of at least one antigen over-represented in the prostate gland or an immunologically effective portion thereof; an expression system capable of generating in situ said antigen or portion; a naked DNA encoding such antigen and portion; and an anti-idiotypic antibody or fragment thereof which mimics said antigen or portion.

In vivo methods for making anti-idiotypic antibodies and compositions comprising the antibodies.

Belonging to the field of molecular biology, the invention in particular relates to an anti-idiotypic nano antibody based zearalenone green immunoassay method. According to the invention, the zearalenone monoclonal antibody 2D3 is employed to immunize alpaca, and the leukocyte total RNA is extracted to construct a phage displayed nano antibody library; the 2D3 antibody is adopted as the target, four rounds of affinity enrichment panning are conducted to lower the coating concentration and competitive elution concentration round by round, and a positive phage zearalenone anti-idiotypic nano antibody with good specificity can be obtained. The invention employs the zearalenone anti-idiotypic nano antibody substitute zearalenone standard ELISA method to determine naturally polluted corn and feed samples, and performs comparison with the HPLC detection result, the two methods have good correlation, and R2 is 0.997, thus proving that the zearalenone anti-idiotypic nano antibody substitute standard method has accurate and reliable result and is an effective and feasible green immunoassay method.

The invention belongs to the field of molecular biology, and particularly relates to an application of an ochratoxin A anti-idiotypic nano-antibody used as a ochratoxin A standard substitute. The present invention obtains the ochratoxin A anti-idiotypic nano-antibody with an amino acid sequence shown in SEQ ID NO: 1. According to ELISA standard curves of standard ochratoxin A and an ochratoxin A anti-idiotypic antibody, under the same inhibition ratio, corresponding relationship curves of the concentration of the ochratoxin A and the concentration of the ochratoxin A anti-idiotypic antibody are established. Besides, the results are subjected to exponential regression analysis to obtain a corresponding relationship between the the ochratoxin A and the ochratoxin A anti-idiotypic antibody. The corresponding relationship can be applied to the detection and analysis of ochratoxin A in agricultural products. The immunodetection method that the ochratoxin A anti-idiotypic nano-antibody replaces the standard ochratoxin A has accurate and reliable results, and is an effective and feasible method for green immunoassay.

The invention provides a carrier assembly carrying a gene element combination, a recipient cell library, a preparation and screening method and an application, the recipient cell library is formed byfusing cells and the carrier assembly, and the carrier assembly at least carries three gene elements, respectively a plurality of first gene elements encoding one or more idiotypic synNotch receptors,respectively; a second gene element carrying one or more gene loops; a third gene element encoding one or more idiotypic chimeric antigen receptors. Wherein, when the first genetic element encodes one idiotypic synNotch receptor, the third genetic element must encode at least three idiotypic chimeric antigen receptors, and when the third genetic element encodes one idiotypic chimeric antigen receptor, the first genetic element must encode three idiotypic synNotch receptors. The gene loop is pre-programmed, a regulatory homeopathic factor is combined with a transcription factor, upon activation of the synNotch receptor encoded by the first gene element, the chimeric antigen receptor encoded by the third gene element is controllably expressed.

The invention belongs to the field of molecular biology, in particular to relates to an ochratoxin A anti-idiotypic nano-antibody and a preparation method thereof, wherein the amino acid sequence of ochratoxin A anti-idiotypic nano-antibody is shown in SED ID No:1. The antibody uses ochratoxin A monoclonal antibody to immunize alpaca, and constructs a bacteriophage display nanometer antibody library by extracting the total RNA of its white blood cells, and the library capacity is high and the diversity is good; taking ochratoxin A monoclonal antibody as the target, three round of affinity enrichment and eluting are used to reduce the coating concentration and competitive eluting concentration one by one, and the positive bacteriophage ochratoxin A anti-idiotypic nano-antibody gene is transformed into the expressed strain; after induction, purification and identification, the protein form nano-antibody VHH2-24. With excellent performance is obtained.

The present invention relates to the modification of immunoglobulin molecules in which one or more cysteine ​​residues in the variable region which form intrachain disulfide bonds are replaced by amino acids which do not contain a sulfhydryl group and thus do not form disulfide bonds. The ability of these modified immunoglobulin molecules to induce an anti-idiotypic response is enhanced. The present invention further provides a method for treating or preventing tumors and / or infectious diseases using the modified immunoglobulin of the present invention.